StockData
Johnson & Johnson logo

Johnson & Johnson (JNJ) operating KPIs

JNJNYSEPharmaceutical PreparationsFiscal year ends January 3
Financials through Q2 FY2026, quarter ended Jun 28, 2026Last filing: 10-Q on Oct 21, 2026Score 12/3043% above fair value
$273.20−2.00 (-0.73%)

Close on Oct 30, 2026Market cap $658.38BP/E 31.7Yield 1.88%

Johnson & Johnson cOVID-19 Vaccine (Ad26.COV2.S) [reported through FY2024Q4] — Worldwide reported growth YoY (%) (%)

Form 8-K EX-99.2 Segment Sales Schedule

Latest, Q3 2024
-97.7%
Period ended Sep 29, 2024
Change on a year earlier
-6.2 pts
-91.5% in Q3 2023
History
9 quarters
Since Q3 2022
Sources
9
Documents cited below

Quarterly history

Hover a value to see the sentence it was read from; calculated values show their formula

PeriodEndedCOVID-19 Vaccine (Ad26.COV2.S) [reported through FY2024Q4] — Worldwide reported growth YoY (%) (%)Year on yearSource
Q3 2024Sep 29, 2024-97.7%-6.2 ptsForm 8-K (a2024q3exhibit991.htm, filed 2024-10-15) ↗
Q2 2024Jun 30, 2024-39.7%+8.0 ptsForm 8-K (a2024q2exhibit991.htm, filed 2024-07-17) ↗
Q1 2024Mar 31, 2024-96.6%-160.0 ptsForm 8-K (a2024q1exhibit991.htm, filed 2024-04-16) ↗
Q4 2023Dec 31, 2023-93.7%-36.3 ptsForm 8-K (a2023q4exhibit991.htm, filed 2024-01-23) ↗
Q3 2023Oct 1, 2023-91.5%-88.8 ptsForm 8-K (a2023q3exhibit991.htm, filed 2023-10-17) ↗
Q2 2023Jul 2, 2023-47.7%–Form 8-K (a2023q2exhibit991.htm, filed 2023-07-20) ↗
Q1 2023Apr 2, 202363.4%–Form 8-K (a2023q1exhibit991.htm, filed 2023-04-18) ↗
Q4 2022Jan 1, 2023-57.4%–Form 8-K (a2022q4exhibit991.htm, filed 2023-01-24) ↗
Q3 2022Oct 2, 2022-2.7%–Form 8-K (a2022q3exhibit991.htm, filed 2022-10-18) ↗

Cite this data

StockData. (2026). Johnson & Johnson COVID-19 Vaccine (Ad26.COV2.S) [reported through FY2024Q4] — Worldwide reported growth YoY (%) (%), quarterly Q3 2022–Q3 2024 [Data set]. Compiled from Johnson & Johnson SEC filings and investor materials. https://stockdatahq.com/stocks/jnj/kpis/drug_covid19_rep_yoy

See every metric in the Johnson & Johnson KPI table. Data updated Oct 25, 2026.